As court case looms, Bris­tol My­ers touts la­bel ex­pan­sion for Breyanzi

As Bris­tol My­ers Squibb braces for a court bat­tle over a cost­ly de­lay — at least for Cel­gene share­hold­ers — for its CAR-T lym­phoma treat­ment Breyanzi, the phar­ma gi­ant is tout­ing a la­bel ex­pan­sion in the sec­ond-line set­ting.

Breyanzi, al­so known as liso-cel, snagged a win on Fri­day in adults with large B-cell lym­phoma (LB­CL) who: don’t re­spond to chemother­a­py, or re­lapse with­in 12 months; don’t re­spond or re­lapse af­ter 12 months; or are not el­i­gi­ble for hematopoi­et­ic stem cell trans­plant af­ter chemo due to their age or co­mor­bidi­ties.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.